In August 2021, RDIF and partners will publish initial data on the immunogenicity of the combined use of the AstraZeneca vaccine and the Sputnik V vaccine in Azerbaijan.
AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential...
The state registry notes that the trials will last until late 2026 and will involve 360 patients. The vaccine will be administered via an intramuscular injection.
Sputnik V pioneered the vaccine cocktail approach with two shots. The tests conducted by the Gamaleya Center have demonstrated validity of this approach.